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Background: High mobility group protein box 1 (HMGB1) is a DNA binding protein located in nucleus. It is
released into extracellular fluid where it acts as a novel proinflammatory cytokine which interacts with Toll like
receptor 4 (TLR4) to activate nuclear factor-κB (NF-κB). This sequence of events is involved in tumor growth and
progression. However, the effects of HMGB1, TLR4 and NF-κB on epidermal tumors remain unclear.
Methods: Human epidermal tumor specimens were obtained from 96 patients. Immunohistochemistry was used to
detect expression of HMGB1, TLR4 and NF-κB p65 in human epidermal tumor and normal skin specimens. Western
blot analysis was used to detect the expression of NF-κB p65 in epithelial cell nuclei in human epidermal tumor
and normal tissues.
Results: Immunohistochemistry and western blot analysis indicated a progressive but statistically significant
increase in p65 expression in epithelial nuclei in benign seborrheic keratosis (SK), precancerous lesions (PCL), low
malignancy basal cell carcinoma (BCC) and high malignancy squamous cell carcinoma (SCC) (P <0.01). The level of
extracellular HMGB1 in SK was significantly higher than in normal skin (NS) (P <0.01), and was higher than in SCC
but without statistical significance. The level of TLR4 on epithelial membranes of SCC cells was significantly higher
than in SK, PCL, BCC and NS (P <0.01). There was a significant positive correlation between p65 expression in the
epithelial nuclei and TLR4 expression on the epithelial cell membranes (r = 0.3212, P <0.01).
Conclusions: These findings indicate that inflammation is intensified in parallel with increasing malignancy. They
also indicate that the TLR4 signaling pathway, rather than HMGB1, may be the principal mediator of inflammation
in high-grade malignant epidermal tumors. Combined detection of p65 in the epithelial nuclei and TLR4 on the
epithelial membranes may assist the accurate diagnosis of malignant epidermal tumors.
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The most common forms of human epidermal tumors
include seborrheic keratosis, precancerous lesions such
as Bowen's disease or bowenoid papulosis, and basal or
squamous cell carcinoma. Seborrheic keratosis is a be-
nign form of hyperplasia involving epidermal basaloid
cells and keratinocytes. Bowen's disease is very similar to
squamous cell carcinoma. Atypical squamous cells pro-
liferate throughout the entire thickness of the epidermis
without invading the dermis. Bowenoid papulosis has a
histological resemblance to Bowen's disease. In this con-
dition atypical keratinocytes are seen at all levels of the* Correspondence: flgong@163.com
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reproduction in any medium, provided the orepidermis, but the cells are less atypical than those seen
in Bowen's disease. Both conditions have the potential to
progress into squamous cell carcinoma.
Basal cell carcinoma is a slow-growing, locally invasive
malignant skin tumor with low metastatic potential. It
begins in the deep basal cell layer of the epidermis and
is characterized by cancerous nests of basaloid cells that
extend into the dermis. Squamous cell carcinoma begins
as a locally invasive malignant skin tumor. Cancerous nests
of atypical squamous cells arise from different layers of
the epidermis and extend irregularly into the dermis. Both
the malignant and metastatic potential of squamous cell
carcinoma are relatively high.
The mechanism of tumorigenesis and progression has
been shown to be related to the local inflammatorytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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These tumors are not generally associated with pathogenic
infection, suggesting that endogenous factors trigger local
inflammation via the release of damage associated mol-
ecule pattern (DAMP) molecules, containing high mobil-
ity group protein box 1 (HMGB1) and heat shock protein
70 (HSP70) [4,5].
HMGB1 is a DNA binding protein located in nucleus,
which is released into the extracellular fluid in the pres-
ence of inflammation and cell necrosis [6,7]. Extracellu-
lar HMGB1 is, therefore, considered to be an important
proinflammatory cytokine which acts by binding to toll-
like receptor 4 (TLR4) receptors [8-10]. TLR4 is con-
trolled by pattern recognition receptors (PRR) which are
able to distinguish between pathogens and DAMP. It is
predominantly expressed in antigen-presenting cells (APC)
including dendritic cells (DC), macrophages and also in
tumor cells.
Extracellular HMGB1 binds to TLR4 and causes mye-
loid differentiation primary response gene 88 (MyD88)
to activate nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) [11]. Activated NF-κB is trans-
ported to the nucleus from the cytoplasm, where it induces
expression of inflammatory factors and promotes cell prolif-
eration and anti-apoptosis. In this way it plays an important
role in tumor genesis and progression [12].
It has been recognized that HMGB1 plays an import-
ant role in autoimmunity disease and cancers [13], and
HMGB1, TLR4 and NF-κB have all been shown to par-
ticipate in the progression and metastasis of malignant
tumors [14,15]. However, the effects of these mediators
in seborrheic keratosis, precancerous lesions, basal cell
carcinoma and squamous cell carcinoma have not been
clarified. We, therefore, investigated their involvement
in the different types of skin tumors primarily by explor-
ing the relationship between HMGB1-TLR4 pathway re-
lated inflammation and tumor development.Methods
Subjects and specimens
Human epidermal tumor specimens were obtained from
28 patients with seborrheic keratosis, 12 patient with
precancerous lesions, 21 patients with basal cell carcinoma,
and 28 patients with squamous cell carcinoma. Tumor
diagnosis was based on clinical and histopathological
criteria. A 3-week 'washout' period from the effects of
radiotherapy or immunotherapy was implemented before
specimen collection. Participants with immune deficiency
diseases were excluded from the study.
Normal skin specimens were obtained from seven healthy
subjects undergoing surgical circumcision or orthopaedic
procedures. Pathological examination of each specimen was
performed using hematoxylin-eosin stained sections.The study was performed in accordance with the Dec-
laration of Helsinki 1964 and its later amendments. The
protocol was approved by the Clinic Research Ethics
Board of Tongji Medical College. All participants pro-
vided a written informed consent prior to inclusion in
the study.Antibodies and reagents
The antibodies used for immunohistochemistry and western
blot analysis included anti-HMGB1 (EPITOMICS, 2600–1),
anti-TLR4 (Abcam, ab22048), anti-NF-κB p65 (Santa Cruz,
SC-7151), REAL™EnVision Detection Kit (Dako), and anti-
HSP70 (Abcam, ab47455).Immunohistochemistry
EnVision was used to detect expression of HMGB1, TLR4
and NF-κB p65 in human epidermal tumor and normal
skin specimens. HSP70 was also tested in both tumor and
normal specimens.
The 96 tissue specimens were routinely fixed in for-
malin and embedded in paraffin. Sections 4 μm thick
were cut from paraffin-embedded tissue blocks and
mounted on silanized slides. After de-waxing and rehy-
dration, the sections were antigen retrieved with ethyl-
enediamine tetraacetic acid or citric acid, incubated with 3%
H2O2 for 10 min and blocked with 5% BSA for 20 min. The
specimens were then incubated with the primary antibodies
(anti-HMGB1 1:800, anti-TLR4 1:200, anti- NF-κB p65
1:200, anti-HSP70 1:100) for 24 h at 4°C. Next the second-
ary antibodies was added (ChemMateTMEnVision +/HRP)
and the specimens were incubated for 45 min, followed by
the addition of 50 to 100 μL of diaminobenzidine (DAB).
Dehydration, transparence, mounting and microscopic
examination were prepared using routine procedures. The
specimens were photographed with a Nikon Eclipse Ti-SR
microscope equipped with a Nikon DS-U3 digital camera.
Negative controls were obtained by omitting the primary
antibodies.
The immunohistochemistry grading of the nucleus,
cytoplasm, cell membrane, cell or intercellular space was
undertaken semi-quantitatively by two blinded pathologists.
The average scores were used for analysis. The scoring sys-
tem was as follows: 0 = no staining, 1 = light brown yellow,
2 = brown and 3 = dark brown staining. Ten fields were
counted on each slide at 400 x magnification. The average
positive expression on each slide was scored as: 1 = <25%,
2 = 25 to <50%, 3 = 50 to <75% and 4= > 75%. The product
of the positive expression percentage and degree of staining
scores for each slide provided a final score where: 0 to 1
point was negative (−), 2 to 3 points was weakly positive
(+), 4 to 6 points was moderately positive (+ +), and >6
points was strongly positive (+ + +).
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Western blot analysis was used to detect the expression
of NF-κB p65 in epithelial cell nuclei in human epidermal
tumor and normal tissues. Dermis and subcutaneous tis-
sues were removed from the specimens and the epidermis
was cut into small pieces for western blot analysis. Epithe-
lial nuclear proteins were prepared from the tissues using
a cytoplasmic/nuclear extraction kit. Equal amounts of
cytoplasmic and nuclear extracts were subjected to 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to nitrocellulose membranes.
The membranes were blocked overnight at 4°C in buffer
containing 5% non-fat dried milk in phosphate buffered
saline (PBS) and 0.1% Tween-20. The membranes were
then blotted for 2 h at room temperature with the pri-
mary antibody, anti-NF-κB p65, diluted at 1:500. The
membrane-bound antibodies were labeled using horse-
radish peroxidase-conjugated (HRP) anti-IgG diluted at
1:3000. Histone H3 was used as a loading control. An
enhanced chemiluminescence system (Pierce) was used
for detection.Statistical analysis
Statistical analysis was undertaken using Stata version 11.0
software. Data were expressed as the means and standard
errors (±SEM). Between-group differences were analyzed
by one-way analysis of variance (ANOVA) followed by
Bonferroni method for normally distributed datasets. The
Kruskal-Wallis test followed by Nemenyi Multiple Com-
parison test was used for skewed datasets. The correl-
ation analysis was performed using Spearman’s correlation
test. Values of P <0.05 were considered statistically signifi-
cant, and P <0.01 were considered extremely statistically
significant.Results
Expression of HMGB1 in human epidermal tumors
In benign seborrheic keratosis (SK), HMGB1 exhibited
diffuse strong positive expression in squamous epithelial
nuclei with little evidence of positive focal expression in
the cytoplasm. Extracellular HMGB1 was also extensively
present in epithelial intercellular spaces. In both the nu-
cleus and cytoplasm of inflammatory cells, there was
strong positive diffusive expression of HMGB1. HMGB1
was also present in the nucleus and cytoplasm of vascu-
lar endothelial cells (Figure 1a and 1b).
In precancerous lesions (PCL), HMGB1 exhibited dif-
fusive positive expression in the epithelial nuclei with
focal expression in the cytoplasm. Scattered expression
of HMGB1 was seen in the epithelial intercellular spaces
of these cells. The nucleus and cytoplasm of associated
inflammatory and vascular endothelial cells showed dif-
fusive positive expression of HMGB1 (Figure 1c and 1d).In low malignant basal cell carcinoma (BCC), there was
diffuse moderate positive expression of HMGB1 in the
cancerous epithelial nuclei, and the cytoplasm exhibited
focal positive expression. Occasional sporadic expression
of HMGB1 was seen in the intercellular spaces together
with positive expression in the nucleus and cytoplasm of
associated inflammatory and vascular endothelial cells
(Figure 1e and 1f).
In highly malignant squamous cell carcinoma (SCC),
there was relatively weak diffuse positive expression of
HMGB1 in the cancerous epithelial nuclei, but minimal
expression in the cytoplasm and scattered expression of
HMGB1 in the epithelial intercellular spaces. There was
positive expression of HMGB1 in associated inflammatory
cells, both in the nucleus and cytoplasm, together with
positive expression of HMGB1 in the nucleus and cyto-
plasm of vascular endothelial cells (Figure 1g and 1h).
Interestingly, HMGB1 exhibited strong positive diffuse
expression in the nuclei of normal squamous epithelial
cells and occasional positive focal expression in the cyto-
plasm. There was minimal HMGB1 expression in the
intercellular spaces of the normal squamous epithelium
and there were few inflammatory cells showing minimal
evidence of nuclear or cytoplasmic expression of HMGB1.
However, both the nucleus and cytoplasm of vascular
endothelial cells in normal skin showed a strong positive
expression of HMGB1 (Figure 1i).
Analysis of variance showed the expression of HMGB1 in
epithelial intercellular spaces of benign seborrheic keratosis
was significantly higher than in normal skin (P =0.0025),
but there was no significant difference between seborrheic
keratosis and highly malignant squamous cell carcinoma
(Figure 1j). Expression of HMGB1 in the epithelial nuclei
of highly malignant squamous cell carcinoma was signifi-
cantly lower than in normal skin and in benign seborrheic
keratosis (P = 0.003), but there was no significant differ-
ence between seborrheic keratosis, precancerous lesions,
basal cell carcinoma and normal skin (Figure 1k).
Expression of HMGB1 in inflammatory cells of sebor-
rheic keratosis, precancerous lesions, basal cell carcinoma
and squamous cell carcinoma was significantly higher than
in normal skin (P = 0.0024); HMGB1 expression in inflam-
matory cells of benign seborrheic keratosis increased non-
signigicantly (Figure 1l).
Expression of TLR4 in human epidermal tumors
In benign seborrheic keratosis (SK) and precancerous le-
sions (PCL), there were diffuse positive expression of TLR4
on epithelial cell membranes (Figure 2a and 2b). In basal
cell carcinoma (BCC), TLR4 expression was seen on cell
membranes of the cancerous epithelium (Figure 2c) and in
highly malignant squamous cell carcinoma (SCC), there
was a strong membrane positive expression of TLR4 on al-
most all of the cancerous epithelium (Figure 2d). In normal
Figure 1 Expression of HMGB1 in epidermal tumors and normal skin by IHC EnVision (magnification × 400). (a) to (i). Positive expression of
HMGB1 was located in the nucleus, cytoplasm, cell, and (or) intercellular space after stimulation of inflammation or cell necrosis. The red arrow shows
HMGB1 expression in the epithelial intercellular space, the black arrow shows positive HMGB1 expression in epithelial cell nuclei, the orange arrow
shows HMGB1 expression in the epithelial cell cytoplasm, the blue arrow shows HMGB1 expression in an inflammatory cell, and the green arrow
shows HMGB1 expression in a vascular endothelial cell. (j). **P < 0.01 of HMGB1 in epithelial intercellular spaces in SK as compared in NS. (k). **P < 0.01
of HMGB1 in epithelial cell nuclei in NS and SK as compared in SCC. (l). **P <0.01 as compared HMGB1 in inflammatory cells in NS. The error bars
show the standard error of the mean (SEM).
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sion on the epithelial cell membranes (Figure 2e).
In squamous cell carcinoma, expression of TLR4 on
epithelial cell membranes was significantly higher than
in seborrheic keratosis, precancerous lesions, basal cell
carcinoma and normal skin (P = 2.3e-5). There was no
significant difference between TLR4 expression in sebor-
rheic keratosis, precancerous lesions, basal cell carcinoma
and normal skin (Figure 2f).Expression of NF-κB p65 in human epidermal tumors
In benign seborrheic keratosis (SK), p65 exhibited rela-
tively weak expression in the epithelial nuclei but there
was evidence of focal expression in the cytoplasm. In the
associated inflammatory cells there was relatively strong
p65 expression in the nucleus, and focal positive expres-
sion in the cytoplasm. In vascular endothelial cells there
was weak expression of p65 in the nucleus and focal posi-
tive expression in the cytoplasm (Figure 3a and 3b).There was weak expression of p65 in the nucleus and
cytoplasm of precancerous lesion (PCL) epithelial cells.
There was also weak p65 expression in the nucleus of
associated inflammatory cells with focal positive expres-
sion in the cytoplasm. Expression of p65 expression was
sporadic in the nucleus and cytoplasm of vascular endo-
thelial cells (Figure 3c).
In malignant basal cell carcinoma (BCC), p65 was
expressed in the epithelial nuclei and there was positive
focal expression in the cytoplasm. In associated inflam-
matory cells, there was weak p65 expression in the nu-
cleus and focal expression in the cytoplasm, and there
was weak p65 expression in the nucleus and cytoplasm
of vascular endothelial cells (Figure 3d).
Malignant squamous cell carcinoma (SCC) showed rela-
tively high p65 expression in the nucleus and diffuse posi-
tive expression in the cytoplasm. p65 was also expressed
in the nucleus of associated inflammatory cells, with
sporadic positive expression in cytoplasm, together with
evidence of expression in the nucleus and cytoplasm of
Figure 2 Expression of TLR4 in epidermal tumors and normal skin by IHC EnVision (magnification × 400). (a) to (e). Positive expression of
TLR4 was located on the epithelial membrane (purple arrow). (f). **P <0.01 as compared TLR4 on epithelial cell membranes in SCC. The error bars
represent the standard error of the mean (SEM).
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By contrast, in normal skin (NS), there was almost no
p65 expression in the epithelial nuclei but focal positive
expression was found in the epithelial cytoplasm. Min-
imal p65 expression was seen in inflammatory cells, and
vascular endothelial cells in normal skin displayed occa-
sional focal p65 expression in the cytoplasm with no nu-
clear expression (Figure 3g).
Analysis of variance indicated that expression of p65
in the epithelial nuclei of different epidermal tumors was
higher than in normal skin. The level of p65 epithelial
nuclear expression was increased progressively from nor-
mal skin, benign hyperplasia, precancerous lesions, low ma-
lignancy to high malignancy tumors (P = 0.0025; Figure 3h).
The expression of p65 in inflammatory cell nuclei asso-
ciated with benign seborrheic keratosis was significantly
higher than in normal skin, precancerous lesions, basal
cell carcinoma and squamous cell carcinoma (P =0.007).
There was no significant difference between precancer-
ous lesions, basal cell carcinoma and squamous cell car-
cinoma and normal skin (Figure 3i).
Western blot detection identified different levels of p65
expression in epithelial nuclei between normal skin and
different tumors. There was almost no p65 expression in
the epithelial nuclei of normal skin, whereas the epithelial
nuclei of malignant basal cell carcinoma and malignant
squamous cell carcinoma showed significant expression.
In addition, p65 expression in squamous cell carcinoma
was higher than in basal cell carcinoma, and p65 expres-
sion in epithelial cell nuclei of precancerous lesions was
higher than in seborrheic keratosis (Figure 3j). Takentogether, these findings suggest p65 expression in epi-
thelial nuclei is upregulated with increased epithelial
cell malignancy.
Expression of HSP70 in human epidermal tumors
Positive expression of HSP70 was found in the epithelial
intercellular spaces in benign seborrheic keratosis (SK)
and precancerous lesions (PCL) (Figure 4a and 4b). There
was also evidence of HSP70 expression in basal cell car-
cinoma (BCC) (Figure 4c), with relatively strong positive
expression in the epithelial intracellular spaces of highly
malignant squamous cell carcinoma (SCC) (Figure 4d).
Minimal HSP70 expression was found in the epithelial
intercellular spaces of normal skin (NS) (Figure 4e).
Analysis of variance showed that HSP70 expression in
epithelial intercellular spaces of squamous cell carcinoma
was significantly higher than in normal skin, seborrheic
keratosis, precancerous lesions and basal cell carcinoma
(P = 0.0077). There was no significant difference in HSP70
expression between seborrheic keratosis, precancerous
lesions, basal cell carcinoma and normal skin (Figure 4f).
Correlation analysis
Spearman's correlation analysis showed that the expression
of p65 in epithelial nuclei of normal skin and different tu-
mors was negatively correlated with HMGB1 levels in the
epithelial cell nuclei (r = −0.3264, P = 0.0012; Figure 5a
and 5g), was negatively correlated with p65 levels in the
inflammatory cell nuclei (r = −0.2496, P = 0.0142; Figure 5b
and 5g), was positively correlated with TLR4 levels on the
epithelial cell membranes (r = 0.3212, P = 0.0014; Figure 5c
Figure 3 Expression of p65 in epidermal tumors and normal skin by 96 IHC EnVision (magnification × 400). (a) to (g). Positive expression of
p65 was located in the cytoplasm, cell, and (or) nucleus after activation. The black arrow shows expression of p65 in the epithelial nucleus, the orange
arrow shows p65 expression in the epithelial cytoplasm, the blue arrow shows p65 expression in an inflammatory cell and the green arrow shows p65
expression in a vascular endothelial cell. (h). **P < 0.01 as compared with p65 in the epithelial nuclei in different groups (i). **P < 0.01 as compared p65
in inflammatory cell nuclei in SK. The error bars represent the standard error of the mean (SEM). (j). Western blot detection of p65 expression in
epithelial nuclei, which increased gradually from NS, SK, PCL, BCC, and to SCC. Histone H3 was used as a loading control.
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epithelial intercellular spaces in normal skin and various
tumor types (r = 0.2844, P = 0.005; Figure 5d and 5g).
In addition, p65 in epithelial nuclei was negatively cor-
related with HMGB1 in the epithelial intercellular spaces
(r = −0.1641, P > 0.05; Figure 5e and 5g), and was nega-
tively correlated with HMGB1 in the inflammatory cells
in normal skin and various tumor types (r = −0.0452,
P > 0.05; Figure 5f and 5g).
Discussion
Human epidermal tumors predominantly include benign
seborrheic keratosis, precancerous lesions Bowen's dis-
ease or bowenoid papulosis, together with malignant
basal cell carcinoma and highly malignant squamous cell
carcinoma. It has been affirmed that some forms of
tumorigenesis are closely related with chronic inflamma-
tion. It has also been reported that chronic hepatitis B
can induce hepatocellular carcinoma, and that chronic
gastritis or gastric ulcer can induce gastric cancer [16].However the role played by HMGB1-TLR4 related in-
flammation in the development of human epidermal tu-
mors remains unknown.
HMGB1 was initially identified as a widely existing
DNA binding protein, which changes the chromatin or
DNA configuration and regulates the transcription complex
formation [6]. HMGB1 is actively produced by macro-
phages and monocytes; it is passively released by damaged
or necrotic cells and is thought to be involved in tumor
cell invasion and metastasis [6,17]. Extracellular HMGB1
has been shown to act as a proinflammatory cytokine,
which binds to TLR4, TLR2 or receptors for advanced
glycation end-products (RAGE) [18-20]. It has also been
reported that HMGB1 activates the MAPK-NF-κB path-
way by interacting with RAGE, and that it plays an im-
portant role in inflammation [20-22].
Toll proteins, first found in Drosophila spp [23,24], are
type I transmembrane proteins [25]. TLR4 is able to
recognize and interact with HMGB1, HSP70 or lipopoly-
saccharide (LPS) to mediate signal transduction pathways,
Figure 4 Expression of HSP70 in epidermal tumors and normal skin by IHC EnVision (magnification × 400). (a) to (e). Positive expression
of HSP70 was located in the epithelial intercellular space as shown by the red arrows. (f). **P <0.01 as compared HSP70 in the epithelial
intercellular spaces in SCC. The error bars represent the standard error of the mean (SEM).
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[26,27]. NF-κB activation and cytokine production are
both thought to be mediated by the MyD88-dependent
pathway [28]. NF-κB is a widely expressed molecule with
a wide range of biological functions including a role in
regulating inflammation [29], cell differentiation, apop-
tosis and cell proliferation [30]. It has also been associatedFigure 5 Correlation analysis of IHC. (a)-(f). The line-charts with SEM sho
Spearman's correlation analysis. (g). The correlation coefficients of Spearma
nuclei as compared HMGB1 in the epithelial cell nuclei ((r = −0.3264, **P <0
inflammatory nuclei (r = −0.2496, *P <0.05). (c) and (g). p65 in epithelial nu
**P <0.01). (d) and (g). p65 in epithelial nuclei as compared HSP70 in the e
epithelial nuclei as compared HMGB1 in the epithelial intercellular spaces
HMGB1 in the inflammatory cells (r = −0.0452, P > 0.05).with tumorgenesis, cell invasion, metastasis and apoptosis
[31-33]. NF-κB family members form two dimers with
homologous or heterologous forms, the most common
dimer being the combination of p50 and p65. NF-κB is
formed by the heterologous dimerization of p50 and p65,
and NF-κB p65 acts an important nucleus transcription
factor [31,34].wing expression of p65 in epithelial cell nuclei and other mediators by
n rho as compared p65 in epithelial nuclei. (a) and (g). p65 in epithelial
.01). (b) and (g). p65 in epithelial nuclei as compared p65 in the
clei as compared TLR4 on the epithelial cell membranes (r = 0.3212,
pithelial intercellular spaces (r = 0.2844, **P <0.01). (e) and (g). p65 in
(r = −0.1641, P > 0.05). (f) and (g). p65 in epithelial nuclei as compared
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anisms [35,36]. Activated NF-κB acts as an anti-apoptotic
factor which induces or up-regulates anti-apoptotic genes
and inhibits apoptosis. The activation of NF-κB causes
cyclinD1 to promote tumor cell proliferation and inde-
pendent division. NF-κB also activates the transcription
and translation of a variety of genes that control tumor
cell adhesion and angiogenesis. These include IL-8, tenascin
C, cell adhesion molecule-1, and matrix metalloproteinase-
3. Various studies have reported that NF-κB expression and
activation are abnormal in breast, thyroid, colon, and stom-
ach cancer, and in some other malignancies [15].
These findings prompted us investigate the diversity of
expression and role played by HMGB1, TLR4 and p65 in
epidermal tumors. We focused our attention on the role
played by extracellular HMGB1 expression in epithelial
intercellular spaces, TLR4 expression on epithelial cell
membranes and p65 expression in epithelial nuclei. We
selected various stages of the epidermal tumor tissues
including seborrheic keratosis, squamous cell carcinoma
in situ, basal cell carcinoma, and squamous cell carcinoma.
The clinical pathological process associated with these
conditions ranged from benign hyperplasia, to precancer-
ous lesions, to low and high-grade malignancy. Normal
skin specimens were used as controls.
Immunohistochemistry results showed that HMGB1 was
differentially expressed in epithelial intercellular spaces,
with seborrheic keratosis and squamous cell carcinoma
showing higher expression than normal skin. This finding
implies that intracellular HMGB1 is released from various
epidermal tumors as a result of cell necrosis cells, enabling
it to act as an extracellular mediator of local inflammation.
However, HMGB1 expression in the intracellular space in
highly malignant squamous cell carcinoma was lower than
in seborrheic keratosis, whereas epithelial nuclear expres-
sion of p65, which indicative of NF-κB activation as well as
inflammation responses, was higher in squamous cell car-
cinoma than in all other cell types (P <0.01). These findings
suggest that HMGB1 maybe not be the principal mediator
of inflammation in highly malignant skin tumors. Correl-
ation analysis showed that expression of HMGB1 in epi-
thelial intercellular spaces was negatively correlated with
p65 in the epithelial nuclei but did not reach statistical
significance, indicating that extracellular HMGB1 may not
play a central role in highly malignant tumors. Further-
more, the expression of HMGB1 in epithelial nuclei in
squamous cell carcinoma was significantly lower than in
normal skin and benign seborrheic keratosis (P <0.01),
suggesting that HMGB1 maybe not account for epider-
mal tumor progression. Instead, HMGB1 in the nucleus
may contribute to the stabilization of DNA and chro-
mosomes in epidermal tumors.
We also found that the membrane expression of TLR4
was higher in squamous cell carcinoma than normal skinand other tumors (P <0.01). TLR4 has been previously
shown to interact with extracellular HMGB1 to activate
NF-κB [11]. Taken together these findings suggest that
TLR4 signaling pathways may act as mediators of increased
inflammation in high malignancy epidermal tumors.
Immunohistochemistry also indicated different levels
of expression of p65 in the epithelial nuclei of epidermal
tumors. There was relatively low epithelial nuclear expres-
sion in benign seborrheic keratosis, with higher levels of
expression in precancerous lesions and basal cell carcin-
oma, relatively strong expression in highly malignant squa-
mous cell carcinoma. In contrast, there was almost no
nuclear expression of p65 in normal skin. Western blot
analysis showed similar results, indicating a tendency to-
wards increased epithelial nuclear expression of p65 with
increased levels of malignancy. The activation and nuclear
translocation of NF-κB are both regulated by its inhibitory
factor IκB. In the resting state, NF-κB dimer and IkB
co-exist as a trimer which is concealed in the cytoplasm.
This process explains why there was almost no squamous
epithelial nuclear p65 expression in normal skin. We also
demonstrated that the level of p65 epithelial nuclear ex-
pression increased progressively but significantly with
tumor evolution from benign hyperplasia, to high level
malignancy (P <0.01), suggesting the inflammation in-
creases in parallel with tumor malignancy. This finding
may be explained by NF-κB p65 activation, which in-
duces the expression of inflammatory factors and pro-
motes cell proliferation and anti-apoptosis.
The expression of NF-κB p65 in the nuclei of inflamma-
tory cells associated with seborrheic keratosis was signifi-
cantly higher than in other tissues (P <0.01). The expression
of HMGB1 in inflammatory cells of seborrheic keratosis
was also relatively strong. These findings suggest that in-
flammation associated with benign epidermal tumors may
be mediated by inflammatory cells, and that inflammation
of epidermal malignant tumors may not originate from in-
flammatory cells but from the malignant squamous epithe-
lial cells themselves.
Correlation analysis showed that expression of p65 in
epithelial nuclei was negatively correlated with HMGB1
expression in the epithelial nuclei in normal skin and in
different tumors (r = −0.3264, P <0.01), further indicating
that HMGB1 is not associated with epidermal tumor
progression. We also showed that expression of p65 in
epithelial nuclei was negatively correlated with p65 expres-
sion in inflammatory cell nuclei (r = −0.2496, P < 0.05),
supporting the hypothesis that inflammation in epidermal
benign tumors is mediated by inflammatory cells. In
addition, the expression of p65 epithelial nuclei was
positively correlated with TLR4 levels on the epithelium
membrane (r = 0.3212, P <0.01), suggesting that p65 and
TLR4 are both involved in epidermal malignant tumor
genesis and progression. Thus, the TLR4-NF-κB p65
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of malignancy.
However, there was no evidence that the same pathway
was so intimately involved in highly malignant squamous
cell carcinoma as expression of HMGB1 in the epithelial
intercellular spaces was not higher than in other tumor
types. It is possible, therefore, that other ligands engaging
TLR4 such as HSP70 may also be involved. HSP70 is con-
tinually expressed in all living organisms and forms a sig-
nificant part of the cellular machinery for protein folding,
for protecting cells from stress [37]. Extracellular HSP70
has been shown to interact with TLR4, activate NF-κB sig-
nals and mediate inflammatory reactions [38-40].
Expression of HSP70 in the epithelial intercellular space
of squamous cell carcinoma was significantly higher than
in normal skin, seborrheic keratosis, precancerous lesions
and basal cell carcinoma (P <0.01), and was positively
correlated with the expression of p65 in epithelial nuclei
(r = 0.2844, P <0.01), indicating that HSP70 may be an-
other mediator of local inflammation in high malignancy
epidermal tumors. These results also explain why HMGB1
expression in epithelial intercellular spaces of high malig-
nancy squamous cell carcinoma was lower than seen with
seborrheic keratosis.
Conclusion
In conclusion, we elucidated that HMGB1 may be one of
mediators resulting in the development of inflammation
in epidermal tumors, but that it did not play a central role
in highly malignant epidermal tumors. In these tumors
the TLR4 signaling pathway appeared to be primarily in-
volved in inducing inflammation. Inflammation intensified
in parallel with the evolution of tumor malignancy and
may also involve HSP70. We also showed that NF-κB p65
and TLR4 might play a significant role in the high malig-
nancy epidermal tumors, and combined detection of TLR4
on epithelial cell membranes and p65 in epithelial cell nu-
clei may be useful for the diagnosis of the epidermal malig-
nant tumors.
Furthermore, expression of HMGB1, TLR4, p65 and
HSP70 in epidermal tumors and normal skin with more
fields of vision could be seen in Additional file 1: Figure S1
of appendant, Additional file 2: Figure S2 of appendant,
Additional file 3: Figure S3 of appendant and Additional
file 4: Figure S4 of appendant, respectively.
Additional files
Additional file 1: Figure S1 of Appendant. Expression of HMGB1 in
epidermal tumors and normal skin by IHC EnVision. (magnification × 400,
larger field).
Additional file 2: Figure S2 of Appendant. Expression of TLR4 in
epidermal tumors and normal skin by IHC EnVision. (magnification × 400,
larger field).Additional file 3: Figure S3 of Appendant. Expression of p65 in
epidermal tumors and normal skin by IHC EnVision. (magnification × 400,
larger field).
Additional file 4: Figure S4 of Appendant. Expression of HSP70 in
epidermal tumors and normal skin by IHC EnVision. (magnification × 400,
larger field).
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